IBDEI0S5 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28298,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28298,1,3,0)
 ;;=3^Follicular lymphoma grade IIIb, unspecified site
 ;;^UTILITY(U,$J,358.3,28298,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,28298,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,28299,0)
 ;;=C82.19^^105^1378^28
 ;;^UTILITY(U,$J,358.3,28299,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28299,1,3,0)
 ;;=3^Follicular lymphoma grade II, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,28299,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,28299,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,28300,0)
 ;;=C82.39^^105^1378^31
 ;;^UTILITY(U,$J,358.3,28300,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28300,1,3,0)
 ;;=3^Follicular lymphoma grade IIIa, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,28300,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,28300,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,28301,0)
 ;;=C82.30^^105^1378^32
 ;;^UTILITY(U,$J,358.3,28301,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28301,1,3,0)
 ;;=3^Follicular lymphoma grade IIIa, unspecified site
 ;;^UTILITY(U,$J,358.3,28301,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,28301,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,28302,0)
 ;;=C82.29^^105^1378^25
 ;;^UTILITY(U,$J,358.3,28302,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28302,1,3,0)
 ;;=3^Follicular lymph grade III, unsp, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,28302,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,28302,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,28303,0)
 ;;=C82.20^^105^1378^30
 ;;^UTILITY(U,$J,358.3,28303,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28303,1,3,0)
 ;;=3^Follicular lymphoma grade III, unspecified, unspecified site
 ;;^UTILITY(U,$J,358.3,28303,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,28303,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,28304,0)
 ;;=C82.09^^105^1378^26
 ;;^UTILITY(U,$J,358.3,28304,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28304,1,3,0)
 ;;=3^Follicular lymphoma grade I, extrnod and solid organ sites
 ;;^UTILITY(U,$J,358.3,28304,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,28304,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,28305,0)
 ;;=C82.10^^105^1378^29
 ;;^UTILITY(U,$J,358.3,28305,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28305,1,3,0)
 ;;=3^Follicular lymphoma grade II, unspecified site
 ;;^UTILITY(U,$J,358.3,28305,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,28305,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,28306,0)
 ;;=C82.00^^105^1378^27
 ;;^UTILITY(U,$J,358.3,28306,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28306,1,3,0)
 ;;=3^Follicular lymphoma grade I, unspecified site
 ;;^UTILITY(U,$J,358.3,28306,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,28306,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,28307,0)
 ;;=C82.90^^105^1378^36
 ;;^UTILITY(U,$J,358.3,28307,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28307,1,3,0)
 ;;=3^Follicular lymphoma, unspecified, unspecified site
 ;;^UTILITY(U,$J,358.3,28307,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,28307,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,28308,0)
 ;;=C82.99^^105^1378^35
 ;;^UTILITY(U,$J,358.3,28308,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28308,1,3,0)
 ;;=3^Follicular lymphoma, unsp, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,28308,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,28308,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,28309,0)
 ;;=C84.00^^105^1378^60
 ;;^UTILITY(U,$J,358.3,28309,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28309,1,3,0)
 ;;=3^Mycosis fungoides, unspecified site
 ;;^UTILITY(U,$J,358.3,28309,1,4,0)
 ;;=4^C84.00
 ;;^UTILITY(U,$J,358.3,28309,2)
 ;;=^5001621
 ;;^UTILITY(U,$J,358.3,28310,0)
 ;;=C84.09^^105^1378^59
 ;;^UTILITY(U,$J,358.3,28310,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28310,1,3,0)
 ;;=3^Mycosis fungoides, extranodal and solid organ sites
 ;;^UTILITY(U,$J,358.3,28310,1,4,0)
 ;;=4^C84.09
 ;;^UTILITY(U,$J,358.3,28310,2)
 ;;=^5001630
 ;;^UTILITY(U,$J,358.3,28311,0)
 ;;=C84.60^^105^1378^8
 ;;^UTILITY(U,$J,358.3,28311,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28311,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-positive, unsp site
 ;;^UTILITY(U,$J,358.3,28311,1,4,0)
 ;;=4^C84.60
 ;;^UTILITY(U,$J,358.3,28311,2)
 ;;=^5001651
 ;;^UTILITY(U,$J,358.3,28312,0)
 ;;=C84.69^^105^1378^10
 ;;^UTILITY(U,$J,358.3,28312,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28312,1,3,0)
 ;;=3^Anaplstc lg cell lymph, ALK-pos, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,28312,1,4,0)
 ;;=4^C84.69
 ;;^UTILITY(U,$J,358.3,28312,2)
 ;;=^5001660
 ;;^UTILITY(U,$J,358.3,28313,0)
 ;;=C84.70^^105^1378^7
 ;;^UTILITY(U,$J,358.3,28313,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28313,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-negative, unsp site
 ;;^UTILITY(U,$J,358.3,28313,1,4,0)
 ;;=4^C84.70
 ;;^UTILITY(U,$J,358.3,28313,2)
 ;;=^5001661
 ;;^UTILITY(U,$J,358.3,28314,0)
 ;;=C84.79^^105^1378^9
 ;;^UTILITY(U,$J,358.3,28314,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28314,1,3,0)
 ;;=3^Anaplstc lg cell lymph, ALK-neg, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,28314,1,4,0)
 ;;=4^C84.79
 ;;^UTILITY(U,$J,358.3,28314,2)
 ;;=^5001670
 ;;^UTILITY(U,$J,358.3,28315,0)
 ;;=C91.40^^105^1378^37
 ;;^UTILITY(U,$J,358.3,28315,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28315,1,3,0)
 ;;=3^Hairy cell leukemia not having achieved remission
 ;;^UTILITY(U,$J,358.3,28315,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,28315,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,28316,0)
 ;;=C91.41^^105^1378^39
 ;;^UTILITY(U,$J,358.3,28316,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28316,1,3,0)
 ;;=3^Hairy cell leukemia, in remission
 ;;^UTILITY(U,$J,358.3,28316,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,28316,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,28317,0)
 ;;=C91.42^^105^1378^38
 ;;^UTILITY(U,$J,358.3,28317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28317,1,3,0)
 ;;=3^Hairy cell leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,28317,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,28317,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,28318,0)
 ;;=C96.4^^105^1378^71
 ;;^UTILITY(U,$J,358.3,28318,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28318,1,3,0)
 ;;=3^Sarcoma of dendritic cells (accessory cells)
 ;;^UTILITY(U,$J,358.3,28318,1,4,0)
 ;;=4^C96.4
 ;;^UTILITY(U,$J,358.3,28318,2)
 ;;=^5001861
 ;;^UTILITY(U,$J,358.3,28319,0)
 ;;=C96.9^^105^1378^50
 ;;^UTILITY(U,$J,358.3,28319,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28319,1,3,0)
 ;;=3^Malig neoplm of lymphoid, hematpoetc and rel tissue, unsp
 ;;^UTILITY(U,$J,358.3,28319,1,4,0)
 ;;=4^C96.9
 ;;^UTILITY(U,$J,358.3,28319,2)
 ;;=^5001864
 ;;^UTILITY(U,$J,358.3,28320,0)
 ;;=C90.00^^105^1378^58
 ;;^UTILITY(U,$J,358.3,28320,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28320,1,3,0)
 ;;=3^Multiple myeloma not having achieved remission
 ;;^UTILITY(U,$J,358.3,28320,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,28320,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,28321,0)
 ;;=C90.01^^105^1378^57
 ;;^UTILITY(U,$J,358.3,28321,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28321,1,3,0)
 ;;=3^Multiple myeloma in remission
 ;;^UTILITY(U,$J,358.3,28321,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,28321,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,28322,0)
 ;;=C90.02^^105^1378^56
 ;;^UTILITY(U,$J,358.3,28322,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28322,1,3,0)
 ;;=3^Multiple myeloma in relapse
 ;;^UTILITY(U,$J,358.3,28322,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,28322,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,28323,0)
 ;;=C91.00^^105^1378^1
 ;;^UTILITY(U,$J,358.3,28323,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28323,1,3,0)
 ;;=3^Acute lymphoblastic leukemia not having achieved remission
 ;;^UTILITY(U,$J,358.3,28323,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,28323,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,28324,0)
 ;;=C91.01^^105^1378^3
 ;;^UTILITY(U,$J,358.3,28324,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28324,1,3,0)
 ;;=3^Acute lymphoblastic leukemia, in remission
